Thinking about investing and profiting from healthcare reform? CVS Caremark Corporation (NYSE:CVS), with its unique position and well defined growth strategies, is poised for more long-term growth. CVS Caremark is the largest integrated pharmacy company in the United States with offerings across the entire spectrum of pharmacy care, including retail and specialty pharmacy, pharmacy benefit management (PBM), and retail health clinics. With its unique market position as the only fully integrated pharmacy company, CVS Caremark Corporation (NYSE:CVS) is able to identify and exploit the emerging opportunities in this fast changing healthcare environment. CVS Caremark continues to focus on growth in its core business to enhance shareholder value.
CVS Caremark Corporation (NYSE:CVS) has the largest and fastest-growing retail clinic business in the United States, Minute Clinic. Minute Clinic offers the value of convenience for patients. While around 30 million Americans are expected to gain certain healthcare coverage over the next few years, Minute Clinic will continue to be a key growth driver for CVS Caremark Corporation (NYSE:CVS) where the management is planning to add 150 new clinics in 2013 and reach over 1,500 clinics by 2017.
Being the market share leader for the managed Medicaid market (31%) and No. 3 for the Medicare Part D market (6.9%), CVS Caremark Corporation (NYSE:CVS) is well positioned to ride the healthcare reform changes. It is estimated that around 11 million people will gain healthcare coverage through Medicaid and 10,000 baby boomers will become Medicare-eligible each day.
While specialty medications dominates the current pipeline of new prescription drugs, the total specialty sales number is expected to double between 2010 and 2016, as expected by the management. CVS Caremark is now expanding its capabilities to manage specialty across both the pharmacy and the medical benefit to expand its share of the fast growing specialty marketplace.
Changing landscape and CVS Caremark’s strategy
With the implementation of the Affordable Care Act and shifts of demographics and consumer behavior, the healthcare industry is expected to change significantly in the next 10 years. CVS Caremark is prepared to fight these major changes. The company will focus on reducing cost and improving quality, as well as improving medication adherence to capture its share of 30 million newly insured Americans (due to the Affordable Care Act). On the other hand, the company will also continue to innovate in branded and biologic specialty drugs, which has the fastest growth in pharmacy. CVS Caremark will address convenience, cost, and quality to maintain its growth.
With its substantial purchasing scale, deep clinical expertise, strong relationships across the clients and consumer spectrums, as well as channel-agnostic approach to prescription delivery, CVS Caremark is expected to continue its growth in the changing environment with its three-pronged strategy, including quality and convenience enhancement, new customer serving channels identification and implementation, and enterprise assets optimization.
CVS Caremark’s retail business has capitalized on the incident where the customers of Express Scripts Holding Company (NASDAQ:ESRX) could not fill their prescription at Walgreen Company (NYSE:WAG)‘s drugstores. CVS Caremark gained over 24 million prescriptions. The management expects to retain at least 60% of the gained scripts throughout the year after Express Scripts and Walgreen resolved the dispute in September, 2012.
Walgreen, on the other hand, had just reported strong May sales, which grew 4.3% as compared to the same period in 2012. Walgreen also stated the percentage of former Express Scripts prescriptions returning to its pharmacies continued to increase in May. Strategically, Walgreen is creating a complete Well Experience for its customers and is expanding its supply agreement with AmerisourceBergen Corp. (NYSE:ABC), which will allow Walgreen to negotiate better pricing for the bulk drugs and gain access to more specialized drugs.